摘要
目的:研究溶葡萄球菌复合酶体外抗流感病毒效果,探寻预防、治疗流感病毒感染的新药和给药途径。方法:应用细胞病变抑制试验和直接免疫荧光法,经不同给药途径、作用时间和剂量,研究溶葡萄球菌复合酶体外抗流感病毒效果。并与已被普遍公认有效的抗流感药物磷酸奥司他韦比较。结果:两种试验方法都显示,两种药物在不同给药方式下,大部分实验组对病毒的抑制作用与对照组相比均有统计学意义(P<0.05)。溶葡萄球菌复合酶1:5稀释后与病毒作用30 m in和磷酸奥司他韦治疗组的抗病毒效果最显著,且两者间差别无统计学意义(P>0.05)。结论:溶葡萄球菌复合酶在体外抗流感病毒中具有较明显的作用,部分实验组的效果和公认的高效抗流感药物磷酸奥司他韦没有差别。在预防流感流行中具有一定的应用前景。
Objective ：To investigate the effect of complex lysostaphin against human influenza A virus in vitro and explore a pre - emergency medicine and its administration for preventing and treating influenza A virus infection. Methods .Two methods including the visual quantitation of antiviral activity based upon inhibition of virus -induced cytopathic effect （CPE） and direct immunofluorescence assay （DIF） were used to evaluate the activity of complex lysostaphin against inflnenza A virus by various approach and dose. Osehamivir, a well -known anti -influenza drug, acted as a comparison in this study, Results： It was demonstrated by both methods that the antiviral activity of both complex lysostaphin and osehamivir in most test groups were significantly more effective than the control group （P 〈0.05 ）. In test groups, both 1：5 complex lysostaphin interacted with virus for 30 minutes and oseltamivir treatment group were most effective, and there was no difference between these two groups （ P 〉 0. 05 ）. Conclusion：It was suggested that complex lysostaphin play an evident role in the inhibition of influenza A virus infection in vitro. There was no significant difference between some complex lysostaphin test group and oseltamivir treatment group. It was indicated that complex lysostaphin could be a potential anti - influenza drug, which was expected as an inexpensive and effective drug in coping with the influenza prevention.
出处
《中国卫生检验杂志》
CAS
2006年第12期1439-1442,共4页
Chinese Journal of Health Laboratory Technology
